SINOPEC SEG (02386) signed an EPC engineering, procurement, and construction contract for the Kazakhstan Dineene and Rubber Project with a total contract value of approximately $1.093 billion.
Sinopec Engineering (02386) announced that recently, the Group signed an EPC engineering, procurement, and construction contract with the project owner, Kazakhstan Diene Polyethylene Limited Liability Company (referred to as "the project owner") for the Kazakhstan Diene Polyethylene and Rubber Project (referred to as "the project"). According to the contract, the Group will provide EPC engineering, procurement, and construction services for the construction of the project, including engineering design, procurement, and construction of relevant process units, utilities, and auxiliary facilities. The contract is worth approximately 1.093 billion US dollars. The total value of the contract will be included in the Group's unfinished contract amount.
SINOPEC SEG (02386) announced that recently, the Group signed an EPC Engineering, Procurement, and Construction contract with Kazakhstan Butadiene Limited Liability Company (hereinafter referred to as the "project owner") for the Butadiene and Rubber project in Kazakhstan (hereinafter referred to as "the project"). According to the contract, the Group will provide EPC engineering services for the construction of the project, including engineering design, procurement, and construction of related process units, utilities, and auxiliary facilities. The contract is valued at approximately $1.093 billion. The total value of the contract will be accounted for in the Group's backlog.
The project is located in the Atyrau region of Kazakhstan, and the project owner is a wholly-owned subsidiary of the Samruk-Kazyna Fund of Kazakhstan. The project focuses on the production of Butadiene rubber, with a capacity to produce 300,000 tons of rubber annually once completed.
Related Articles

New stock news | Cancer early screening track welcomes heavyweight player Amyson submits application to Hong Kong Stock Exchange Core products have been approved by the National Medical Products Administration.

Triple the dose, with a monthly increase of only $50: Novo Nordisk A/S Sponsored ADR Class B (NVO.US) boosts the dose of Wegovy to compete with Eli Lilly and Company's Zepbound (LLY.US).

Nasdaq ETF changes! BlackRock, Inc. (BLK.US) and State Street (STT.US) are squeezing, and Invesco's (IVZ.US) near 20-year monopolistic position is in jeopardy.
New stock news | Cancer early screening track welcomes heavyweight player Amyson submits application to Hong Kong Stock Exchange Core products have been approved by the National Medical Products Administration.

Triple the dose, with a monthly increase of only $50: Novo Nordisk A/S Sponsored ADR Class B (NVO.US) boosts the dose of Wegovy to compete with Eli Lilly and Company's Zepbound (LLY.US).

Nasdaq ETF changes! BlackRock, Inc. (BLK.US) and State Street (STT.US) are squeezing, and Invesco's (IVZ.US) near 20-year monopolistic position is in jeopardy.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


